Investor revolt at Bayer to escalate after CEO keeps his job


Lower market value: Bayer logo sits on the exterior of the company’s pharmaceutical factory in Berlin. Bayer has lost 35 billion euros (US$39bil) in market value, due in large part to subsequent lawsuits that allege the main ingredient of Roundup – the weedkiller Bayer acquired through Monsanto – causes cancer. — Bloomberg

FRANKFURT: The shareholder rebellion at Bayer AG is poised to worsen after its supervisory board ignored an unprecedented no-confidence vote against the leadership of chief executive officer Werner Baumann.

Several top investors of the German chemicals and drugs giant are frustrated with directors’ decision to back Baumann and his strategy that led to the US$63bil takeover of Monsanto, according to people familiar with the matter.

The investors considered the move a sign that Bayer is unwilling to address shareholder concerns, the people said, asking not to be identified because the deliberations are private.

Bayer now needed to consider an overhaul of the oversight board led by Werner Wenning, take a more forthcoming approach in dealing with litigation in the US and conduct a strategic review – including a potential breakup of the conglomerate into crop science and pharmaceutical companies, they said.

At a fractious, 13-hour gathering in Bonn last Friday, more than 55% of shareholders voted against absolving Baumann and other managers of responsibility for their actions in the takeover of agriculture company Monsanto last year.

Bayer has lost 35 billion euros (US$39bil) in market value, due in large part to subsequent lawsuits that allege the main ingredient of Roundup – the weedkiller Bayer acquired through Monsanto – causes cancer.

The lawsuits have multiplied, totalling 13,400 US cases by April 11. Bayer has vowed to fight in court and said there’s no scientific proof that glyphosate causes cancer.

A Bayer representative declined to comment on investors’ call for changes.

In an e-mail on Saturday, Baumann sought to reassure employees, saying “we need to maintain our focus on delivering value for our customers,” according to a person who has seen the communication and asked not to be identified because the information isn’t public.

The vote was heavily influenced by prominent shareholder advisory firms in the US, Baumann wrote.

Bloomberg News reported earlier last week that Baumann could lose the ballot. In a separate motion, some 66% voted to absolve Wenning and the rest of the supervisory board.

While the results aren’t legally binding, it prompted an emergency board meeting that stretched into the early hours of Saturday. — Bloomberg

Get 20% OFF The Star Digital Access

Monthly Plan

RM 13.90/month

RM 11.12/month

Billed as RM 11.12 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 9.87/month

Billed as RM 118.40 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!
Bayer , investor , revolt , CEO , job ,

Next In Business News

A construction boom with an expiry date?
Fund managers bullish on China
Cybersecurity – many agencies but how secure are we?�
A banker fuelling fintech’s rise
WHERE SANCTUARY MEETS SUSTAINABILITY
Luxury is back in fashion
Hospital mergers can�raise competition challenges
SoftBank’s US$50bil investment plan in Malaysia
Banking on Asia’s growth
Battle for UK deposits

Air Pollutant Index

Note: API is calculated based on 24hr running average of the most dominant parameter.

Highest API Readings

    Select State and Location to view the latest API reading

    Others Also Read